source
- GSK CEO outlines £1.9bn cost-saving drive and aims to launch 20 Phase 3 trials by year-endGSK chief executive Luke Miels presented a three‑year plan to make the company more agile and generate significant cost efficiencies. The strategy targets £1.9 billion in annual savings by 2029, wi…
- Alnylam shares tumble 30% even as biotech sector ralliesAlnylam's stock fell about 30% on July 28, 2026, even though the broader biotech market is experiencing a resurgence. The market rebound follows years of a bearish environment, with increased merg…